[1]Hasegawa,Tomoyuki;Yamamoto,Hisashi[Synlett,1998,#8,p.882-884]
[2]Hasegawa,Tomoyuki;Yamamoto,Hisashi[BulletinoftheChemicalSocietyofJapan,2000,vol.73,#2,p.423-428]
[1]CurrentPatentAssignee:ONOPHARMACEUTICALCOLTD-US6392073,2002,B1Locationinpatent:Pagecolumn14
[2]Hasegawa,Tomoyuki;Yamamoto,Hisashi[BulletinoftheChemicalSocietyofJapan,2000,vol.73,#2,p.423-428]
[3]CurrentPatentAssignee:ONOPHARMACEUTICALCOLTD-US6392073,2002,B1Locationinpatent:Pagecolumn14
[4]CurrentPatentAssignee:ONOPHARMACEUTICALCOLTD-US6608221,2003,B1
[5]CurrentPatentAssignee:ONOPHARMACEUTICALCOLTD-US6608221,2003,B1
[1]Hasegawa,Tomoyuki;Yamamoto,Hisashi[BulletinoftheChemicalSocietyofJapan,2000,vol.73,#2,p.423-428]
[2]CurrentPatentAssignee:ONOPHARMACEUTICALCOLTD-US6608221,2003,B1
[3]CurrentPatentAssignee:ONOPHARMACEUTICALCOLTD-US6392073,2002,B1Locationinpatent:Pagecolumn10
[4]Hasegawa,Tomoyuki;Kawanaka,Yasufumi;Kasamatsu,Eiji;Iguchi,Yoichi;Yonekawa,Yoshihira;Okamoto,Masaki;Ohta,Chiaki;Hashimoto,Shinsuke;Ohuchida,Shuichi[OrganicProcessResearchandDevelopment,2003,vol.7,#2,p.168-171]
[1]Hasegawa,Tomoyuki;Yamamoto,Hisashi[Synthesis,2003,#8,p.1181-1186]
[1]Pelotier,Beatrice;Holmes,Ta'id;Piva,Olivier[TetrahedronAsymmetry,2005,vol.16,#8,p.1513-1520]
[2]Pelotier,Beatrice;Holmes,Ta'id;Piva,Olivier[TetrahedronAsymmetry,2005,vol.16,#8,p.1513-1520]
Title: Asymmetric allylic alkylation of acyclic allylic ethers with organolithium reagents.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany) 20120917
Title: Inhibition of the activation of hepatic stellate cells by arundic acid via the induction of cytoglobin.
Journal: Biochemical and biophysical research communications 20120831
Title: Direct regiospecific and highly enantioselective intermolecular α-allylic alkylation of aldehydes by a combination of transition-metal and chiral amine catalysts.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany) 20120305
Title: Neurological diseases as primary gliopathies: a reassessment of neurocentrism.
Journal: ASN neuro 20120101
Title: Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.
Journal: International journal of pharmaceutics 20110715
Title: A systematic review of clinical trials of pharmacological interventions for acute ischaemic stroke (1955-2008) that were completed, but not published in full.
Journal: Trials 20100101
Title: S100b counteracts neurodegeneration of rat cholinergic neurons in brain slices after oxygen-glucose deprivation.
Journal: Cardiovascular psychiatry and neurology 20100101
Title: Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.
Journal: Cardiovascular psychiatry and neurology 20100101
Title: S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond.
Journal: Cardiovascular psychiatry and neurology 20100101
Title: Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease.
Journal: Cardiovascular psychiatry and neurology 20100101
Title: PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation.
Journal: Journal of neuroinflammation 20100101
Title: Immunohistochemical analysis of brain lesions using S100B and glial fibrillary acidic protein antibodies in arundic acid- (ONO-2506) treated stroke-prone spontaneously hypertensive rats.
Journal: Journal of neural transmission (Vienna, Austria : 1996) 20091001
Title: Inflammatory mechanisms in ischemic stroke: therapeutic approaches.
Journal: Journal of translational medicine 20090101
Title: Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice.
Journal: Cellular and molecular neurobiology 20080501
Title: Acute astrocyte activation in brain detected by MRI: new insights into T(1) hypointensity.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20080301
Title: Application of the correlation of in vitro dissolution behavior and in vivo plasma concentration profile (IVIVC) for soft-gel capsules--a pointless pursuit?
Journal: Biological & pharmaceutical bulletin 20071101
Title: Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke.
Journal: Journal of clinical pharmacology 20070401
Title: Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion.
Journal: Brain research 20070302
Title: Effect of arundic acid on serum S-100beta in ischemic stroke.
Journal: Journal of the neurological sciences 20061221
Title: Safety and tolerability of arundic acid in acute ischemic stroke.
Journal: Journal of the neurological sciences 20061221
Title: Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice.
Journal: The Journal of pharmacology and experimental therapeutics 20060801
Title: [Role of the astrocyte-specific protein S100B in acute stroke].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20060601
Title: Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
Journal: Neuropharmacology 20060301
Title: Could treatment with arundic acid (ONO-2506) increase vulnerability for depression?
Journal: Medical hypotheses 20060101
Title: Progressive neurodegenerative disease and pain.
Journal: IDrugs : the investigational drugs journal 20051201
Title: Modulation of astrocytic activation by arundic acid (ONO-2506) mitigates detrimental effects of the apolipoprotein E4 isoform after permanent focal ischemia in apolipoprotein E knock-in mice.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20050601
Title: Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.
Journal: Current drug targets. CNS and neurological disorders 20050401
Title: Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Journal: Brain research 20041224
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040401
Title: Attenuation of a delayed increase in the extracellular glutamate level in the peri-infarct area following focal cerebral ischemia by a novel agent ONO-2506.
Journal: Neurochemistry international 20040101
Title: ONO-2506. Ono.
Journal: Current opinion in investigational drugs (London, England : 2000) 20030701
Title: Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Journal: Journal of the neurological sciences 20030415
Title: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20020601
Title: Tomoyuki Hasegawa, et al. Process Development of ONO-2506: A Therapeutic Agent for Stroke and Alzheimer's Disease. Org. Process Res. Dev.200372168-171.
Title: Kato H, et al. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTPneurotoxicity in mice. Brain Res. 2004 Dec 24;1030(1):66-73.
